Patents by Inventor Jeno Gyuris

Jeno Gyuris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20130330772
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 12, 2013
    Inventors: Sylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Anti-RON antibodies
    Patent number: 8603478
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: December 10, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8580930
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: November 12, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8575318
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: November 5, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • ANTI-FGFR2 ANTIBODIES
    Publication number: 20130288305
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 31, 2013
    Inventors: Zhigang Weng, William M. Winston, JR., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20130203963
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20130203970
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Anti-FGFR2 antibodies
    Patent number: 8481688
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: July 9, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Zhigang Weng, William M. Winston, Jr., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • Anti-ErbB3 antibodies
    Patent number: 8481687
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: July 9, 2013
    Assignee: Aveo Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • TIVOZANIB AND CAPECITABINE COMBINATION THERAPY
    Publication number: 20120252829
    Abstract: A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 4, 2012
    Inventors: Jie Lin, Jeno Gyuris, Feng Jiang, Guangmu Li, Xiaojian Sun
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8273355
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 25, 2012
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • ()
    Patent number: 8268315
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 18, 2012
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Fibroblast growth factor receptor 3 (FGFR3) binding proteins
    Patent number: 8187601
    Abstract: Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 29, 2012
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Zhigang Weng, William M. Winston, Jr., Lyne Breault, Kristan Meetze, Solly Weiler, Jeno Gyuris
  • ANTI-RON ANTIBODIES
    Publication number: 20120027773
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Application
    Filed: July 6, 2011
    Publication date: February 2, 2012
    Inventors: Kerry Whalen, Steve Botega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, JR., Jeno Gyuris
  • ANTI-FGFR2 ANTIBODIES
    Publication number: 20110305687
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Application
    Filed: May 11, 2011
    Publication date: December 15, 2011
    Inventors: Zhigang Weng, William M. Winston, JR., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • ANTI-ERBB3 ANTIBODIES
    Publication number: 20110256154
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 20, 2011
    Inventors: Sylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Botega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20110236377
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 29, 2011
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20110229462
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7943344
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 17, 2011
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7935502
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 3, 2011
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris